Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available medicines for people with MPNST. Methylthioadenosine Phosphorylase (MTAP) loss is a gene mutation that some people have. MTAP loss seems to increase the chance that BMS-986504 can kill MPNST cancer cells. People who are missing MTAP from their tumor may be able to enroll in this study. Treating MPNST based on MTAP loss is considered experimental and is not approved by the US Food and Drug Administration (FDA) for determining whether BMS-98650 will be active against cancer. The purpose of this study is to evaluate the safety and effectiveness of BMS-986504 in participants with MPNST.

NCT Number	NCT07549022
Lead Sponsor	Ankit Mangla, MD
Conditions	Malignant Peripheral Nerve Sheath Tumors, MPNST
Enrollment	17 participants
Start Date	2026-08
Primary Completion	2028-04 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-11